Erratum to: Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications (BMC Health Serv Res. (2016) 16 (130) DOI: 10.1186/s12913-016-1356-z);Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications

BMC Health Services Research

Volumn 16, Issue 1, 2016, Pages

  Kwon, Hye Young ^a   Godman, Brian ^b,c  

^a Mokwon University   (South Korea)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

Generics; Health policy; Korea; Market expansion; Statins

Indexed keywords

ATORVASTATIN; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

AGED; COST; ECONOMICS; EPIDEMIOLOGY; FEMALE; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MALE; MIDDLE AGED; PUBLIC HEALTH; SOUTH KOREA; STATISTICAL MODEL;

AGED; ATORVASTATIN CALCIUM; COSTS AND COST ANALYSIS; DRUGS, GENERIC; FEMALE; HEALTH EXPENDITURES; HEALTH POLICY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERRUPTED TIME SERIES ANALYSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; REPUBLIC OF KOREA;

EID: 84963878369     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/s12913-017-2114-6     Document Type: Erratum

References (50)

1. Kesselheim AS, Misono AS, Lee JL, Stedman MR, Brookhart MA, Choudhry NK, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300(21):2514-26.
2. Corrao G, Soranna D, Arfe A, Casula M, Tragni E, Merlino L, et al. Are generic and brand-name statins clinically equivalent? Evidence from a real data-base. Eur J Intern Med. 2014;25(8):745-50.
3. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential Savings from Substituting Generic Drugs for Brand-Name. Ann Intern Med. 2005;142(11):891-7.
4. Kanavos P. Do generics offer significant savings to the UK National Health Service? Curr Med Res Opin. 2007;23:105-16.
5. Dylst P, Vulto A, Simoens S. Analysis of European policy towards generic medicines. GaBi J. 2014;3(1):34-5.
6. Godman B, Wettermark B, van Woerkom M, Fraeyman J, Alvarez-Madrazo S, Berg C, et al. Multiple policies to enhance prescribing efficiency for established medicines in Europe with a particular focus on demand-side measures: findings and future implications. Front Pharmacol. 2014;5:106.
7. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharm Out. 2013;13(1):59-72.
8. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries: an overview. GaBi J. 2012;1(2):93-100.
9. Kanavos P, Costa-Font J, Seeley E. Competition in off-Patent Drug Markets: Issues, Regulation and Evidence. In: de Ménil G, Portes R, Sinn H-W, editors. Economic Policy 55 July 2008. Oxford: Blackwell Publishing Ltd; 2008. doi: 10.1002/9781444306835.ch3.
10. Dylst P, Vulto A, Simoens S. Societal value of generic medicines beyond cost-saving through reduced prices. Expert Rev Pharm Out. 2015;15(4):701-11.
11. Godman B, Abuelkhair M, Vitry A, Abdu S, Bennie M, Bishop I, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBi J. 2012;1(2):21-35.
12. Godman B, Bishop I, Finlayson AE, Campbell S, Kwon HY, Bennie M. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharm Out. 2013;13(4):469-82.
13. Godman B, Shrank W, Andersen M. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Expert Rev Pharm Out. 2010;10(6):707-22.
14. Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract. 2008;62(3):480-4.
15. Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther. 2010;35(2):139-51.
16. Sakshaug S, Furu K, Karlstad O, Ronning M, Skurtveit S. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol. 2007;64(4):476-81.
17. Woerkom M, Piepenbrink H, Godman B, Metz J, Campbell S, Bennie M, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comparat Eff Res. 2012;1(6):527-38.
18. Jyrkka J, Vartiainen L, Hartikainen S, Sulkava R, Enlund H. Increasing use of medicines in elderly persons: a five-year follow-up of the Kuopio 75 + Study. Eur J Clin Pharmacol. 2006;62(2):151-8.
19. Nobili A, Garrattini S, Mannucci PM. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity. 2011;1:28-44.
20. Murphy C, Bennett K, Fahey T, Shelley E, Graham I, Kenny RA. Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from The Irish Longitudinal Study on Ageing (TILDA). BMJ Open. 2015;5(7):e008017.
21. Kwon HY, Yang BM, Do generics really create savings on drug expenditures? Kor J Health Econ and Policy. 2011;17(4):23-42.
22. Kwon HY, Hong JM, Godman B, Yang BM. Price cuts and drug spending in South Korea: the case of antihyperlipidemic agents. Health Policy. 2013;112:217-26.
23. Lee HJ, Lee TJ. Impact of Price Control on Drug Expenditure and Factors Associated with the Drug Switch among Statins: Analysis of HIRA-NPS Data. Kor J Health Policy and Manag. 2013;23(2):112-23.
24. Bae G, Park C, Lee H, Han E, Kim DS, Jang S. Effective policy initiatives to constrain lipid-lowering drug expenditure growth in South Korea. BMC Health Serv Res. 2014;14:100.
25. Korea Center for Disease Control and Prevention (KCDC). The fourth Korea National Health and Nutrition Examination Survey (KNHANES IV) 2007-2009. Seoul: Ministry of Health and Welfare & Korea Centers for Disease Control and Prevention; 2007.
26. World Health Organization (WHO), ATC/DDD Index 2015. Available at URL: http://www.whocc.no/ddd/definition-and-general-considera/. Accessed 14 May 2015.
27. Littell RC, Pendergast J, Natarajan R. Modeling covariance structure in the analysis of repeated measure data. Stat Med. 2000;19:1793-819.
28. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyze unbiased repeated measures and longitudinal data. Stat Med. 1997;16:2349-80.
29. Diggle PJ. An approach to the analysis of repeated measures. Biometrics. 1988;44:959-71.
30. Vogler S, Zimmerman N. How do regional sickness funds encourage more rational use of medicines, including the increase of generic uptake? A case study from Austria. GaBi J. 2013;2(2):65-75.
31. Cameron A, Laing R. Cost savings of switching private sector consumption from originator brand medicines to generic equivalents. Available at URL: http://www.who.int/healthsystems/topics/financing/healthreport/35MedicineCostSavings.pdf. Accessed 20 Sept 2015.
32. Fraeyman J, Van Hal G, Godman B, Beutels P. The potential influence of various initiatives to improve rational prescribing for proton pump inhibitors and statins in Belgium. Expert Rev Pharm Out. 2013;13(1):141-51.
33. Kim CH, Test of physician-induced demand in Korea, Ph.D Dissertation, 2002 Yonsei University Korea.
34. Iizuka T. Experts' Agency Problems: Evidence from the Prescription Drug Market in Japan. RAND J Econ. 2007;38:844-62.
35. Chen C, Dong W, Shen JJ, Cochran C, Wang Y. Is the Prescribing Behavior of Chinese Physicians Driven by Financial Incentives? Soc Sci Med [Internet]. Elsevier Ltd; 2014;120:40-8. Available from: http://dx.doi.org/10.1016/j.socscimed.2014.05.033.
36. Reynolds L, McKee M. Factors influencing antibiotic prescribing in China: an exploratory analysis. Health Policy. 2009;90(1):32-6.
37. Zeng WXH, Godman B, Finlayson AE, Malmstrom RE. Ongoing initiatives to improve prescribing efficiency in China; statins as a case history. GaBi J. 2014;3(3):122-32.
38. Zeng W, Zhen J, Feng M, Campbell SM, Finlayson AE, Godman B. Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction. J Comparat Eff Res. 2014;3(4):371-86.
39. Orlowski JP, Wateska L. The Effects of Pharmaceutical Firm Enticements on Physician Prescribing Patterns: There's No Such Thing as a Free Lunch. Chest. 1992;102:270-3.
40. Wazana A. Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift?". JAMA. 2000;283:373-80.
41. Dieperink ME, Drogemuller L. Industry-Sponsored Grand Rounds and Prescribing Behavior. JAMA. 2001;285:1443-4.
42. Dana J, Loewenstein G. A Social Science Perspective on Gifts to Physicians from Industry. JAMA. 2003;290:252-5.
43. Liu YM, Yang YHK, Hsieh CR. Financial incentives and physicians' prescription decisions on the choice between brand-name and generic drugs: Evidence from Taiwan. J Health Econ. 2009;28(2):341-9.
44. Rodwin MA. Reforming Pharmaceutical Industry- Physician Financial Relationships: Lessons from the United States. J Law Med Ethics. 2011;39(4):662-70.
45. Nguyen H. The principal-agent problems in health care: Evidence from prescribing patterns of private providers in Vietnam. Health Policy Plan. 2011;26(SUPPL. 1):i53-i62.
46. Yang BM and Kwon HY, TRIPS and New Challenges for Pharmaceutical Sector in South Korea. In: Hans Lofgren and Owain David Williams, The New Political Economy of Pharmaceuticals: Production, Innovation and TRIPS in the Global South, Palgrave Macmillan: 2013.
47. Drug reimbursement list and tariff, as of January 1st, 2014 http://www.hira.or.kr/dummy.do?pgmid=HIRAA030014050000&cmsurl=/cms/information/02/01/06/index.html. Accessed 17 Oct 2014.
48. Godman B, Wettermark B, Hoffmann M, Andersson K, Haycox A, Gustafsson LL. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res. 2009;9(1):65-83.
49. Korea Fair Trade Commission. Corrective measures against illegal customer incentive and resale price maintenance activities of ten pharmaceutical companies, 2007. [press release] http://www.ftc.go.kr/news/ftc/reportView.jsp?report-data-no=2819&tribu-type-cd=&report-data-div-cd=&currpage=1&searchKey=1&searchVal=10&44060;&stdate=&enddate=. Accessed 14 May 2015.
50. Olsson E, Ingman P, Ahmed B, Kalvemark Sporrong S. Pharmacist-patient communication in Swedish community pharmacies. Res Social Adm Pharm. 2014;10(1):149-55.